Future studies are needed to determine if these findings translate to human CAD patients, but this study strongly supports the development of VCAM-1 targeted agents as non-invasive diagnostic tools to longitudinally monitor the progression of peripheral and coronary atherosclerosis. This evidence concerns the gene VCAM1 and coronary atherosclerosis.